Finance

Lists
500087:BOM
Cipla Ltd
1 313,70 INR
+0,80%
(+10,40) 1D
12-окт., 15:57:14 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 500087...
Open
1 305,00 INR
High
1 316,50 INR
Low
1 300,25 INR
Mkt. cap
1,06 трлн
Avg. vol.
43,53 миң
Volume
43,36 миң
Dividend
0,99%
Quarterly dividend
3,25 INR
Ex-dividend date
2026-ж., 5-июн.
P/E ratio
31,50
52-wk high
1 672,20 INR
52-wk low
1 165,55 INR
EPS
41,70 INR
Shares outstanding
805,67 млн
No. of employees
31 миң
Open
1 305,00 INR
High
1 316,50 INR
Low
1 300,25 INR
Mkt. cap
1,06 трлн
Avg. vol.
43,53 миң
Volume
43,36 миң
Dividend
0,99%
Quarterly dividend
3,25 INR
Ex-dividend date
2026-ж., 5-июн.
P/E ratio
31,50
52-wk high
1 672,20 INR
52-wk low
1 165,55 INR
EPS
41,70 INR
Shares outstanding
805,67 млн
No. of employees
31 миң
News stories
From web sources and news partners
Profile
Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India. Wikipedia
About Cipla Ltd
CEOUmang Vohra
Employees31,4 миң
Founded1935
HeadquartersМамбай, Махараштра, Индия
SectorPharmaceutical industry
Websitecipla.com
Last report
2026-ж., 23-июл.
Fiscal period
Q1 2027
9,76 INR / 10,42 INR
-6,36%miss
Revenue / Est. (INR)
70,77 млд / 71,42 млд
-0,91%miss
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
74,47 млд
69,63 млд
65,80 млд
70,77 млд
Cost of goods sold
24,98 млд
26,32 млд
25,10 млд
26,67 млд
Cost of revenue
24,98 млд
26,32 млд
25,10 млд
26,67 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13,15 млд
13,25 млд
28,23 млд
14,97 млд
Operating expense
33,52 млд
33,54 млд
33,30 млд
35,22 млд
Total operating expenses
58,50 млд
59,86 млд
58,39 млд
61,89 млд
Operating income
15,98 млд
9,77 млд
7,41 млд
8,88 млд
Other non operating income
2,69 млд
2,06 млд
-5,35 млд
2,11 млд
EBT including unusual items
18,54 млд
8,93 млд
6,99 млд
10,80 млд
EBT excluding unusual items
18,54 млд
11,69 млд
4,51 млд
10,80 млд
Income tax expense
5,00 млд
2,19 млд
1,57 млд
2,95 млд
Effective tax rate
27,00%
24,48%
22,44%
27,29%
Other operating expenses
17,40 млд
17,51 млд
2,51 млд
17,20 млд
Net income
13,51 млд
6,76 млд
5,55 млд
7,89 млд
Net profit margin
18,14%
9,71%
8,43%
11,15%
Earnings per share
16,72
10,94
6,86
9,76
Interest and investment income
-
-
2,07 млд
-
Interest expense
-131,80 млн
-140,30 млн
-69,70 млн
-170,30 млн
Net interest expenses
-131,80 млн
-140,30 млн
2,00 млд
-170,30 млн
Depreciation and amortization charges
2,97 млд
2,78 млд
2,56 млд
3,04 млд
EBITDA
18,73 млд
12,00 млд
9,82 млд
11,29 млд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору